Clinical Trials
Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024
Read More: Roche Date: June 17, 2024
AstraZeneca Showcases the P-III (ECHO) Study Data of Calquence Combination Regimen for Mantle Cell Lymphoma at EHA 2024
Read More: AstraZeneca Date: June 17, 2024
HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024
Read More: HUTCHMED Date: June 17, 2024
Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024
Read More: Regeneron Date: June 17, 2024
AstraZeneca’s Imfinzi Combined with Chemotherapy Gains the US FDA’s Approval to Treat Endometrial Cancer
Read More: AstraZeneca Date: June 18, 2024
Takeda Reports Topline Data from P-III (SKYLINE and SKYWAY) Studies of Soticlestat for Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS)
Read More: Takeda Date: June 18, 2024
AstraZeneca Reports Data from the P-III (CAPItello-290) Study of Truqap Combined with Chemotherapy to Treat Triple-Negative Breast Cancer
Read More: Astrazeneca Date: June 19, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma
Read More: Tubulis Date: June 20, 2024
Neumora Therapeutics Commences the P-Ib Trial of NMRA-511 to Treat Agitation Due to Alzheimer’s Disease
Read More: Neumora Therapeutics Date: June 21, 2024
Aphaia Pharma Reports the P-II Study Results of APHD-012 Among Pre-Diabetic Individuals
Read More: Aphaia Pharma Date: June 21, 2024
Regulatory
Amgen’s Blincyto (Blinatumomab) Receives the US FDA’s Approval to Treat B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
Read More: Amgen Date: June 17, 2024
Merck’s Capvaxive Receives the US FDA’s Accelerated Approval to Prevent Invasive Pneumococcal Disease and Pneumonia in Adults
Read More: Merck Date: June 18, 2024
Johnson & Johnson Reports the BLA Submission of SC Amivantamab to the US FDA for Treating Non-Small Cell Lung Cancer
Read More: Johnson & Johnson Date: June 18, 2024
AbbVie’s Skyrizi Gains the US FDA’s Approval for Treating Ulcerative Colitis
Read More: AbbVie Date: June 19, 2024
Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A
Read More: Sobi Date: June 19, 2024
AstraZeneca’s Truqap in Combination with Faslodex Receives EC’s Approval for Treating Breast Cancer
Read More: AstraZeneca Date: June 20, 2024
Dizal’s Golidocitinib Gains the NMPA’s Approval to Treat Peripheral T-Cell Lymphoma
Read More: Dizal Date: June 20, 2024
Sarepta Therapeutics’ Elevidys Gains the US FDA’s Label Expansion Approval for Duchenne Muscular Dystrophy
Read More: Sarepta Therapeutics Date: June 21, 2024
Johnson & Johnson Reports sBLA Submission of Tremfya to the US FDA for Treating Crohn’s Disease
Read More: Johnson & Johnson Date: June 21, 2024
BMS Reports the EMA’s Validation of the Application for Subcutaneous Opdivo
Read More: BMS Date: June 21, 2024
Pharma
Takeda Enters into an Option Agreement with Ascentage Pharma for Olverembatinib to Treat Chronic Myeloid Leukemia
Read More: Takeda Date: June 17, 2024
Ascidian Therapeutics Join Hands with Roche to Discover and Develop RNA Exon Editing Therapies for Neurological Diseases
Read More: Ascidian Therapeutics & Roche Date: June 19, 2024
Belharra Therapeutics Partners with Sanofi to Discover New Small Molecules Addressing Immunological Diseases
Read More: Belharra Therapeutics & Sanofi Date: June 19, 2024
Biophytis and Blanver Collaborate to Develop BIO101 for Treating Multiple Indications
Read More: Biophytis & Blanver Date: June 20, 2024
Alivexis and Melodia Therapeutics Join Forces to Develop MDI-0151 for Inflammatory Diseases
Read More: Alivexis & Melodia Therapeutics Date: June 21, 2024
Biosimilar
Alvotech and Advanz Pharma Team Up to Commercialize AVT06/AVT29 (Biosimilar, Eylea) in Europe
Read More: Alvotech & Advanz Date: June 18, 2024
MedTech
Roche’s Digital Pathology Solution Bags the US FDA’s Clearance for its Use in Diagnosis
Read More: Roche Date: June 18, 2024
Roche Introduces In-Situ Hybridisation (ISH) Test for the Diagnosis of B-cell Lymphoma
Read More: Roche Date: June 20, 2024
M&A
Boston Scientific Reports the Acquisition of Silk Road Medical
Read More: Boston Scientific & Silk Road Medical Date: June 19, 2024
BioTech
OSE Immunotherapeutics Highlights Preclinical Data of mRNA Therapeutic Platform to Treat Inflammatory and Autoimmune Disorders at FOCIS 2024
Read More: OSE Immunotherapeutics Date: June 20, 2024
